Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

AstraZeneca (AZ) has announced promising results from a late-stage study of its C5 complement inhibitor Ultomiris ...

Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s Ultomiris (ravulizumab) ...

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed ...

Ultomiris is already approved for the rare diseases Atypical Haemolytic Uremic Syndrome (aHUS), and Paroxysmal Nocturnal Haemoglobinuria, which at first glance would seem a million miles away from ...

Novartis has unveiled further data for Fabhalta (iptacopan), reinforcing its position in the paroxysmal nocturnal ...

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers ...